{"bill":{"bill_id":1720130,"change_hash":"efce097480389ac13b76b7adea0a58ba","session_id":2006,"session":{"session_id":2006,"state_id":20,"year_start":2023,"year_end":2023,"prefile":0,"sine_die":0,"prior":0,"special":0,"session_tag":"Regular Session","session_title":"2023 Regular Session","session_name":"2023 Regular Session"},"url":"https:\/\/legiscan.com\/MD\/bill\/SB954\/2023","state_link":"https:\/\/mgaleg.maryland.gov\/mgawebsite\/Legislation\/Details\/SB0954?ys=2023RS","completed":0,"status":1,"status_date":"2023-02-24","progress":[{"date":"2023-02-24","event":1},{"date":"2023-02-24","event":9}],"state":"MD","state_id":20,"bill_number":"SB954","bill_type":"B","bill_type_id":"1","body":"S","body_id":50,"current_body":"S","current_body_id":50,"title":"Overdose Response Program \u2013 Opioid Overdose Reversal Drugs \u2013 Choice of Formulation and Dosage","description":"Requiring the Maryland Department of Health to allow certain entities provided opioid overdose reversal drugs by the Department under the Overdose Response Program to choose the formulation or dosage of opioid overdose reversal drugs approved by the federal Food and Drug Administration with which the entity is to be provided.","pending_committee_id":1936,"committee":{"committee_id":1936,"chamber":"S","chamber_id":50,"name":"Rules"},"referrals":[{"date":"2023-02-24","committee_id":1936,"chamber":"S","chamber_id":50,"name":"Rules"}],"history":[{"date":"2023-02-24","action":"First Reading Senate Rules","chamber":"S","chamber_id":50,"importance":1}],"sponsors":[{"people_id":4686,"person_hash":"3pfyqc9p","party_id":"1","state_id":20,"party":"D","role_id":2,"role":"Sen","name":"Katherine Klausmeier","first_name":"Katherine","middle_name":"Ann","last_name":"Klausmeier","suffix":"","nickname":"","district":"SD-008","ftm_eid":5467115,"votesmart_id":6175,"opensecrets_id":"","knowwho_pid":195266,"ballotpedia":"Katherine_Klausmeier","bioguide_id":"","sponsor_type_id":1,"sponsor_order":1,"committee_sponsor":0,"committee_id":0,"state_federal":0}],"sasts":[{"type_id":5,"type":"Crossfiled","sast_bill_number":"HB571","sast_bill_id":1694357}],"subjects":[{"subject_id":22396,"subject_name":"Public Health"},{"subject_id":3182,"subject_name":"Drugs"},{"subject_id":3277,"subject_name":"Health"},{"subject_id":255963,"subject_name":"Health, Department of"},{"subject_id":318535,"subject_name":"Medical Treatments"},{"subject_id":318536,"subject_name":"Opioids"},{"subject_id":3189,"subject_name":"Substance Abuse"}],"texts":[{"doc_id":2717059,"date":"2023-02-24","type":"Introduced","type_id":1,"mime":"application\/pdf","mime_id":2,"url":"https:\/\/legiscan.com\/MD\/text\/SB954\/id\/2717059","state_link":"https:\/\/mgaleg.maryland.gov\/2023RS\/bills\/sb\/sb0954f.pdf","text_size":86162,"text_hash":"e1b4b655790053b166e3faca7062b4a0"}],"votes":[],"amendments":[],"supplements":[],"calendar":[]}}